脂肪性肝炎
肝细胞癌
四氯化碳
肝硬化
脂肪变性
肝癌
医学
胃肠病学
内科学
脂肪肝
化学
疾病
有机化学
作者
Sijing Li,Omar Motiño,Flavia Lambertucci,Hui Chen,Gerasimos Anagnostopoulos,Léa Montégut,U. Nogueira-Recalde,Maria Chiara Maiuri,Guido Kroemer,Isabelle Martins
出处
期刊:Methods in molecular biology
日期:2024-01-01
卷期号:: 57-65
标识
DOI:10.1007/978-1-0716-3694-7_4
摘要
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD). Obesity is a known risk factor of NASH, which, in turn, increases the risk of developing cirrhosis (liver scarring) and hepatocellular carcinoma (HCC). In addition to being a potentially life-threatening condition, public health concerns surrounding NASH are amplified by the lack of FDA-approved treatments. Although various preclinical models reflecting both the histopathology and the pathophysiological progression of human NASH exist, most of these models are diet-based and require 6–13 months for NASH symptom manifestation. Here, we describe a simple and rapid-progression model of NASH and NASH-driven HCC in mice. Mice received a western diet equivalent (WD; i.e., a high-fat, high-fructose, and high-cholesterol diet), high-sugar water (23.1 g/L fructose and 18.9 g/L glucose), and weekly intraperitoneal injections of carbon tetrachloride (CCl4) at a dose of 0.2 μL/g of body weight. The resulting phenotype, consisting in liver fibrosis and HCC, appeared within 24 weeks of diet/treatment initiation and presented similar histological and transcriptomic features as human NASH and NASH-driven HCC, thereby supporting the adequacy of this preclinical model for the development and evaluation of drugs that can prevent or reverse these diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI